Get the Stockscreener App
69.32
2.53%
-1.80
Cg Oncology Inc stock is traded at $69.32, with a volume of 368.76K.
It is down -2.53% in the last 24 hours and up +0.87% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$71.12
Open:
$71.02
24h Volume:
368.76K
Relative Volume:
0.37
Market Cap:
$6.11B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-29.59
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
-3.52%
1M Performance:
+0.87%
6M Performance:
+28.82%
1Y Performance:
+165.19%
1-Day Range:
$68.96
$71.02
1-Week Range:
$68.00
$73.60
52-Week Range:
$23.65
$77.00
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
69.32 | 6.11B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
TradingKey - TradingKey
CG Oncology Inc (CGON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CG Oncology Inc (CGON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intratumoral Cancer Therapies Market to Reach USD 3.15 Billion - openPR.com
CGON (CGON) insider files to sell 50,000 shares after option exercise - Stock Titan
CG Oncology appoints David Fela as vice president to strengthen quality control focus - Traders Union
CGON|CG Oncology Inc|Price:69.200|Chg%:-1.920 - TradingKey
Biotech Darling CG Oncology Suddenly Falls Out Of Favor - TipRanks
CG Oncology: Priced To Perfection On Future Pipeline Success - Seeking Alpha
CG Oncology director Leonard Post disposes of 1,000 shares for $71,170 - Bitget
CG Oncology (CGON) Surges 3.4% as Bullish Momentum Builds Above Key SupportRounding Bottom - dars.gov.et
CG Oncology (CGON) director sells 1,000 shares at $71.17 - Stock Titan
Ani Pharmaceuticals Announces Intent To Appeal Rulings In CG Oncology Matter - TradingView
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter - The Manila Times
ANI Pharmaceuticals to Appeal Delaware Ruling Denying Post-Trial Motions in CG Oncology Asset Dispute - Quiver Quantitative
Form 144 CG ONCOLOGY For: 15 July By Investing.com - Investing.com Nigeria
CG Oncology, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
CG Oncology: Advancing Toward a Potential Breakthrough in Bladder Cancer Treatment - Kalkine
CG Oncology (CGON) director exercises options, sells 24,165 shares - Stock Titan
CG Oncology (CGON) Declines Moderately as Biotech Sector Faces HeadwindsMomentum ETF - dars.gov.et
CG Oncology Stock Stumbles After Hitting Fresh Peak - TipRanks
CG Oncology Stock Gains 12% in Three Months: What's Driving It? - Yahoo Finance
Form DEF 14A CG Oncology Inc For: 10 July By Investing.com - Investing.com Australia
Form 144 CG Oncology For: 10 July By Investing.com - Investing.com South Africa
Cognition Therapeutics (NASDAQ: CGON) insider plans sale of 20,237 shares - Stock Titan
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating - Moomoo
CG Oncology (CGON) Investor presentation Summary - Quartr
CG Oncology (CGON) Jefferies Global Healthcare Conference 2026 Summary - Quartr
CG Oncology (CGON) Bank of America Global Healthcare Conference 2026 Summary - Quartr
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $77 to $108 - Moomoo
CGONCg Oncology Inc Options - Finviz
CGON,QURE Volatility & Greeks - Finviz
CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase - Quiver Quantitative
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Director POST LEONARD E - Moomoo
Form 144 CG ONCOLOGY INC For: 1 July By Investing.com - Investing.com UK
Insider sale notice: CGON (NASDAQ: CGON) 3,928 shares via exercise - Stock Titan
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
CG Oncology stock hits all-time high at 75.79 USD - Investing.com
CG Oncology stock hits all-time high at 75.79 USD By Investing.com - Investing.com Nigeria
Monday insider trading: CG Oncology director buys $24.8M stake By Investing.com - Investing.com South Africa
Monday insider trading: CG Oncology director buys $24.8M stake - Investing.com
Cg oncology director Brian Liu buys $24.8 million in shares - Investing.com India
Top Insider Makes Massive Bet on CG Oncology’s Future - TipRanks
Form PRE 14A CG Oncology Inc For: 29 June By Investing.com - Investing.com India
Form 4 CG Oncology Inc For: 29 June By Investing.com - Investing.com Nigeria
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):